The 3mg donepezil tablet that was developed by Hyundai Pharmaceutical is being reviewed by the health authorities for reimbursement in Korea. No other tablet formulation of donepezil 3mg currently exists in Korea’s reimbursement list.

Therefore, the Health Insurance Review and Assessment Service is seeking for the most appropriate development target product to determine its price.

Hyundai Pharmaceutical received approval for Hipezil Tab 3mg (Donepezil hydrochloride monohydrate) on the 28th of last month. Hipezil Tab 3mg is indicated to slow the progression of symptoms of dementia associated with Alzheimer's disease and is the first 3mg donepezil formulation introduced to the market. <